Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 6/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.43 |
| ▸ | PRKDC | P78527 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.43 |
| ▸ | PI4KA | P42356 | 1/20 | 0.43 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.43 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.42 |
| ▸ | EP300 | Q09472 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17795410 | 0.91 | CREBBP (0.54) | WDR5NOTUMCREBBPLRRK2KDM1A | |
| SCHEMBL17809587 | 0.90 | CREBBP (0.50) | WDR5NOTUMCREBBPLRRK2KDM1A | |
| SCHEMBL17809508 | 0.88 | KDM1A (0.49) | WDR5NOTUMCREBBPKDM1ABRD4 | |
| SCHEMBL19538914 | 0.82 | NOTUM (0.51) | NOTUMCREBBPKDM1ATRIM24PRKDC | |
| SCHEMBL17806217 | 0.82 | NOTUM (0.51) | WDR5NOTUMCREBBPLRRK2KDM1A | |
| SCHEMBL21255170 | 0.79 | PRMT5 (0.45) | CREBBPKDM1ATRIM24PRKDCBRD4 | |
| SCHEMBL17809604 | 0.79 | KDM1A (0.50) | WDR5NOTUMCREBBPKDM1ABRD4 | |
| SCHEMBL17806201 | 0.77 | CREBBP (0.50) | WDR5NOTUMCREBBPLRRK2KDM1A | |
| SCHEMBL21024258 | 0.77 | CREBBP (0.50) | WDR5CREBBPLRRK2KDM1ABRD4 | |
| SCHEMBL28281659 | 0.77 | CYP11B2 (0.51) | WDR5NOTUMCREBBPBRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3224258-B1 | 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS | GENENTECH INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-9763922-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333406-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | WDR5 621/4885NOTUM 3529/4885CREBBP 6/4885 |
| US-20160158207-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC10 | WDR5 621/4885NOTUM 3529/4885CREBBP 6/4885 |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | WDR5 1460/4885NOTUM 2078/4885CREBBP 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.